- Home
- CHRO vs APM Comparison
CHRO vs APM Comparison
Compare CHRO & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- APM
- Stock Information
- Founded
- CHRO 2002
- APM 2010
- Country
- CHRO United States
- APM United Kingdom
- Employees
- CHRO N/A
- APM N/A
- Industry
- CHRO
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- APM Health Care
- Exchange
- CHRO Nasdaq
- APM Nasdaq
- Market Cap
- CHRO 4.2M
- APM 4.0M
- IPO Year
- CHRO 2024
- APM 2018
- Fundamental
- Price
- CHRO $0.60
- APM $0.76
- Analyst Decision
- CHRO Strong Buy
- APM
- Analyst Count
- CHRO 1
- APM 0
- Target Price
- CHRO N/A
- APM N/A
- AVG Volume (30 Days)
- CHRO 121.3K
- APM 69.7K
- Earning Date
- CHRO 11-13-2024
- APM 12-27-2024
- Dividend Yield
- CHRO N/A
- APM N/A
- EPS Growth
- CHRO N/A
- APM N/A
- EPS
- CHRO N/A
- APM N/A
- Revenue
- CHRO N/A
- APM $431,378.00
- Revenue This Year
- CHRO N/A
- APM $157,729.10
- Revenue Next Year
- CHRO N/A
- APM N/A
- P/E Ratio
- CHRO N/A
- APM N/A
- Revenue Growth
- CHRO N/A
- APM N/A
- 52 Week Low
- CHRO $0.45
- APM $0.46
- 52 Week High
- CHRO $6.00
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- CHRO 48.49
- APM 41.12
- Support Level
- CHRO $0.55
- APM $0.73
- Resistance Level
- CHRO $0.71
- APM $0.78
- Average True Range (ATR)
- CHRO 0.10
- APM 0.09
- MACD
- CHRO -0.00
- APM 0.04
- Stochastic Oscillator
- CHRO 23.98
- APM 64.47
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.